在心力衰竭中使用Interleukin-1信号抑制剂,可保持和减少喷射分数
E V Samoilova1, D А Chepurnova1, S N Nasonova1
1Academician E.I. Chazov National Medical Research Center of Cardiology, Moscow.
Kardiologiia
|December 29, 2025
概括
在急性不补偿性心力衰竭 (ADHF) 中,保留喷射分数 (HFpEF) 的患者与减少喷射分数 (HFrEF) 的患者相比,显示出较高水平的IL-1受体对抗剂 (IL-1Ra) 和可溶性IL-1受体II型 (sIL-1R2). 这表明HFpEF中的炎症反应和IL-1中和更强烈.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 心力衰竭分为HFpEF和HFrEF,具有不同的病理生理机制.
- 介素-1 (IL-1) 信号传递在炎症和心血管疾病中起作用.
- 了解不同类型心力衰竭中的IL-1通路动态对于向治疗至关重要.
研究的目的:
- 为了比较HFpEF与HFrEF患者的IL-1,sIL-1R2和IL-1Ra的循环水平.
- 评估这些水平在急性不补偿性心力衰竭 (ADHF) 和稳定条件下.
- 研究对炎症反应和IL-1中和的影响.
主要方法:
- 测量了IL-1,sIL-1R2和IL-1Ra的血度.
- 该研究包括在ADHF期间和12个月后在稳定状态下随访的HFpEF和HFrEF患者.
- 统计分析比较了不同患者群体和疾病之间的生物标志物水平.
主要成果:
- 在ADHF期间,IL-1R2和IL-1Ra度明显高于稳定状态,IL-1Ra增加了3.5倍.
- 在ADHF中,HFpEF患者的IL-1水平较低,而IL-1R2和IL-1Ra与HFrEF患者相比较高.
- 在稳定条件下,IL-1是不可检测的,HFpEF和HFrEF之间的IL-1R2和IL-1Ra的差异减少.
结论:
- ADHF涉及HFpEF和HFrEF之间的差异性炎症反应和IL-1中和.
- 与HFrEF患者相比,HFpEF患者表现出更明显的炎症反应和IL-1中和.
- 这些发现强调了在心力衰竭治疗策略中考虑IL-1通路调节的重要性.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
01:30Heart Failure V: Medical Management
196
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:22Heart Failure Drugs: Diuretics
763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
01:29Heart Failure II: Pathophysiology
663
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
663
01:22Heart Failure Drugs: β-Blockers
727
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
727